A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Trial To Assess The Safety And Efficacy Of Certolizumab Pegol (CDP870), Dosed Subcutaneously In Patients With Moderate To Severe Crohn's Disease.

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Trial To Assess The Safety And Efficacy Of Certolizumab Pegol (CDP870), Dosed Subcutaneously In Patients With Moderate To Severe Crohn's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2017 Outcomes of a population pharmacokinetic model assessing exposure-response relationship of of certolizumab pegol using pooled data from nine clinical trials of certolizumab pegol induction and maintenance therapy in patients with Crohns disease, including C87005,C87031,C87032, C87037, C87042, C87043,C87047, C87048 and C87085, published in the Alimentary Pharmacology and Therapeutics Journal.
    • 10 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top